Matthew Biegler
Stock Analyst at Oppenheimer
(3.44)
# 966
Out of 5,114 analysts
89
Total ratings
38.75%
Success rate
9.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Upgrades: Outperform | $14 | $7.70 | +81.82% | 7 | Jan 26, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $45 → $48 | $26.07 | +84.12% | 10 | Dec 11, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $25.35 | +77.51% | 1 | Dec 4, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $10.73 | +39.79% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $12.55 | +75.30% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $17.58 | +59.27% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.88 | +325.53% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $5.74 | +21.95% | 1 | Jul 31, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.59 | +467.82% | 2 | May 14, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $160 | $13.99 | +1,043.67% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $13.38 | +236.32% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $139.60 | -17.62% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $32.99 | +60.65% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $32.27 | +2.26% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $2.51 | +696.81% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $7.03 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $10.89 | +28.56% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $8.06 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.20 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $11.16 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.42 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.25 | - | 2 | Dec 22, 2022 |
Relay Therapeutics
Jan 26, 2026
Upgrades: Outperform
Price Target: $14
Current: $7.70
Upside: +81.82%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $45 → $48
Current: $26.07
Upside: +84.12%
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $25.35
Upside: +77.51%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $10.73
Upside: +39.79%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $12.55
Upside: +75.30%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $17.58
Upside: +59.27%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.88
Upside: +325.53%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $5.74
Upside: +21.95%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.59
Upside: +467.82%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $13.99
Upside: +1,043.67%
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $13.38
Upside: +236.32%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $139.60
Upside: -17.62%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $32.99
Upside: +60.65%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $32.27
Upside: +2.26%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.51
Upside: +696.81%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $7.03
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $10.89
Upside: +28.56%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $8.06
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.20
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $11.16
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.42
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.25
Upside: -